Connect Biopharma Holdings Limited Financing Cash Flow
Connect Biopharma Holdings Limited (CNTB) reported Financing Cash Flow of $18.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.33M, a 724.22% increase year-over-year.
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $17.62M, a 881000.00% increase year-over-year.
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $715.00K, a 574.53% increase year-over-year.
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $215.00K.
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for fiscal 2025 was $1.09M, a 381.50% increase from fiscal 2024.
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for fiscal 2024 was $227.00K, a 404.44% increase from fiscal 2023.
- Connect Biopharma Holdings Limited net cash provided by (used in) financing activities for fiscal 2023 was $45.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $18.95M 10-Q · filed 2026-08-12 | $19.66M derived: sum of 3 quarters · filed 2026-08-12 | $19.88M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $17.62M 10-Q · filed 2026-05-12 | $18.34M derived: sum of 2 quarters · filed 2026-05-12 | $18.55M derived: sum of 3 quarters · filed 2026-05-12 | $18.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $715.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $930.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.09M derived: sum of 3 quarters · filed 2026-08-12 | $1.09M 10-K · filed 2026-03-31 |
| 2025-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $376.00K derived: sum of 2 quarters · filed 2026-08-12 | $378.00K 10-Q · filed 2025-11-12 | $484.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $163.00K 10-Q · filed 2026-08-12 | $269.00K derived: sum of 3 quarters · filed 2026-08-12 | $269.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-12 | $108.00K derived: sum of 2 quarters · filed 2026-05-12 | $108.00K derived: sum of 3 quarters · filed 2026-05-12 | $229.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $106.00K derived: sum of 2 quarters · filed 2026-03-31 | $227.00K derived: sum of 3 quarters · filed 2026-03-31 | $227.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $121.00K derived: sum of 2 quarters · filed 2025-11-12 | $121.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $121.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $121.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $45.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |